Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Net Income towards Common Stockholders fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7314.91%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Net Income towards Common Stockholders is -$39.3 million, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Net Income towards Common Stockholders registered a high of $207.3 million during Q1 2024, and its lowest value of -$41.0 million during Q2 2022.
  • Over the past 5 years, Protagonist Therapeutics' median Net Income towards Common Stockholders value was -$33.2 million (recorded in 2024), while the average stood at -$7.5 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Net Income towards Common Stockholders tumbled by 33545.02% in 2021 and then skyrocketed by 71479.61% in 2024.
  • Protagonist Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$37.2 million in 2021, then increased by 7.77% to -$34.3 million in 2022, then skyrocketed by 179.78% to $27.3 million in 2023, then surged by 381.7% to $131.7 million in 2024, then crashed by 129.88% to -$39.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$39.3 million for Q3 2025, versus -$34.8 million for Q2 2025 and -$11.7 million for Q1 2025.